1000 Winter Street
United States - Map
TESARO, Inc., an oncology-focused biopharmaceutical company, engages in the identification, acquisition, development, and commercialization of oncology therapeutics and supportive care products in the United States, Europe, and other international markets. Its product portfolio consist of the Rolapitant, a neurokinin-1 receptor antagonist, which is in Phase III clinical trials for the prevention of chemotherapy induced nausea and vomiting; Niraparib, an orally active and potent poly polymerase inhibitor that has undergone a Phase I clinical trial in cancer patients; and TSR-011, an orally available anaplastic lymphoma kinase inhibitor, which is in Phase 1/2 dose escalation clinical trials in cancer patients. The company was founded in 2010 and is headquartered in Waltham, Massachusetts.
|Mr. Leon O. Moulder Jr., M.B.A.,
Co-Founder, Chief Exec. Officer and Director
|Dr. Mary Lynne Hedley Ph.D.,
Co-Founder, Pres, Chief Scientific Officer and Director
|Mr. Richard J. Rodgers ,
Co-Founder and Consultant
|Mr. Edward C. English ,
Principal Financial Officer, Principal Accounting Officer and VP of Fin. & Admin.
|Ms. Jennifer Davis ,
Sr. Director of Corp. Devel. & Investor Relations
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|